Hunan Weite Pharmaceutical Co., Ltd.

To investigate the relative bioavailability of a single oral (fasting/postprandial) test preparation of sacubitril-valsartan sodium tablets [Specification: 200 mg based on sacubitril-valsartan (sacubitril 97 mg/valsartan 103 mg)] and a reference preparation [trade name: Nusintuo, specification: 200 mg based on sacubitril-valsartan (sacubitril 97 mg/valsartan 103 mg)] in healthy adult Chinese subjects, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the drug. Secondary objective: To evaluate the safety of a single oral dose of 1 tablet of the test preparation and the reference preparation (fasting/postprandial) in healthy Chinese subjects.

To investigate whether there are differences in the extent and rate of absorption between the test preparation sitagliptin metformin tablets (II) (Hunan Weite Pharmaceutical Co., Ltd., specifications: sitagliptin phosphate 50 mg (as free base)/metformin hydrochloride 850 mg) and the reference preparation sitagliptin metformin tablets (II) (trade name: Janumet®; MSD Pharma (Singapore) Pte. Ltd., specifications: sitagliptin phosphate 50 mg (as free base)/metformin hydrochloride 850 mg) after a single oral administration in Chinese healthy subjects under fasting and fed conditions, to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting and fed conditions, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

To investigate whether there are differences in the extent and rate of absorption between the test preparation sitagliptin phosphate tablets (Hunan Weite Pharmaceutical Co., Ltd., specification: 100 mg) and the reference preparation sitagliptin phosphate tablets (trade name: JANUVIA®; Merck Sharp & Dohme B.V., specification: 100 mg) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.